Business Context and Reporting Period
This Form 8-K was filed by Illumina, Inc. on November 25, 2019. The report discloses the execution of a Separation Agreement with a senior executive.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It details specific compensation terms for a departing executive:
- Base Salary Payment: One year of annual base salary totaling $560,000.
- Health Insurance: COBRA premiums for 12 months.
- Performance Bonus: Eligibility for a variable compensation payment of up to $504,000.
- Other Benefits: Access to professional outplacement services and executive physical benefits for 12 months.
Material Changes
The material change reported is the confirmed departure of Garret Hampton, Senior Vice President of Clinical Genomics, effective January 10, 2020. This follows a prior disclosure on August 29, 2019, regarding his intent to leave.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or general risk factors. The primary contingency noted is the finalization of the Separation Agreement, which is referenced in full and will be filed as an exhibit to the Company's Form 10-K for the fiscal year ending December 29, 2019.
Investor Verification Checklist
- Verify the final payout amount for the performance-based cash payment, as it is capped at $504,000 but contingent on plan terms.
- Review the full Separation Agreement when filed as an exhibit to the 2019 Form 10-K for additional terms.
- Monitor the Company's announcement regarding the replacement for the Senior Vice President of Clinical Genomics.